Want to join the conversation?
$BSX reported 3Q15 worldwide organic revenue growth of 5% and operational revenue growth of 9%, including the impact from Bayer and AMS acquisitions. $BSX is updating its FY15 adjusted EPS guidance in the range of $0.90-92 and organic revenue growth estimate is now at 4-5%.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.